Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Acyclic nitrogen double bonded to acyclic nitrogen – acyclic...
Reexamination Certificate
2005-07-12
2005-07-12
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Acyclic nitrogen double bonded to acyclic nitrogen, acyclic...
C514S407000, C534S753000, C534S769000, C534S774000, C534S775000, C548S364100, C548S364400, C548S364700, C548S365100, C548S365700
Reexamination Certificate
active
06916798
ABSTRACT:
The present invention relates to compounds of formula I that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula I or pharmaceutical compositions comprising compounds of formula I to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. The invention also relates to methods for inhibiting Aurora-2 activity and for treating or preventing Aurora-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I. The invention also relates to methods for inhibiting cyclin-dependent kinase-2 activity and for treating or preventing inhibiting cyclin-dependent kinase-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I.
REFERENCES:
patent: 2908677 (1959-10-01), Straley et al.
patent: 4666933 (1987-05-01), Jelich et al.
patent: 4743615 (1988-05-01), Jelich et al.
patent: 4968687 (1990-11-01), Findeisen et al.
patent: 4968714 (1990-11-01), Lunkenheimer et al.
patent: 4988718 (1991-01-01), Findeisen et al.
patent: 1072597 (2001-01-01), None
patent: 47-49167 (1972-12-01), None
patent: WO-01/09121 (2001-02-01), None
patent: WO-01/32653 (2001-05-01), None
Sueda et al., Chemical Abstracts, 80:38356, 1974.
Etman et al., J. Indian Chem. Soc., 67, 213-215, 1990.
Junek et al., Chemical Abstracts, 110:153632, 1989.
Ledrut et al., Chemical Abstracts, 70:37708, 1969.
Mancy et al., Chemical Abstracts, 122:265785, 1995.
Mustafa et al., Chemical Abstracts, 69:2800, 1968.
Prakash et al., Chemical Abstracts, 66:55436, 1967.
Saharia et al., Chemical Abstracts, 81:105390, 1974.
Sekily et al., Carbohydrate Research, 112, 151-157, 1983.
Abass et al., Synthetic Communications, 31(21), 3361-3376, 2001.
Al-Hajjar, Chemical Abstracts, 88:136510, 1978.
Baig et al., J. Chem. Soc., Perkin Transactions 1, 8, 1811-1819, 1982.
Elnagdi et al., Chemical Abstracts, 77:152053, 1972.
Abass, et al., “Chemistry of Substituted Quinolinones. III”, Synthesis and Reactions of Some Novel 3-Pyrazolyl-2-Quinolinones,Synthetic Communications, 31(21):3361-3376, 2001.
Hafez, et al., “New Heterocyclo-Substituted Pyrazolo[3,4-b]Pyridine Derivatives”,Collect. Czech. Chem. Commun. 58: 1198-1202, 1993.
Keats, et al., “Mass Spectral Fragmentation Pattern of 5-Methyl-4-[Phenylamino)Methylene]2,4-Dihydro-3H-Pyrazol-3-One and Its 2-Methyl and 2-Phenyl Derivatives”,J. Heterocyclic Chem., 19: 55-59, 1982.
Arnost Michael J.
Green Jeremy
Pierce Albert
Choate Hall & Stewart LLP
Powers Fiona T.
Robidoux Andrea L.C.
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of GSK-3 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of GSK-3 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of GSK-3 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388643